Cadrenal Therapeutics, Inc. Common Stock

CVKD

NASDAQ

Healthcare

Biotechnology

Ponte Vedra, FL, US4 employeescadrenal.com

$4.75

-0.15(-3.06%)

Mkt Cap $11M

$4.25

$17.36

52-Week Range

At a Glance

AI-generated

FY2025 saw Cadrenal Therapeutics post wider operating and net losses alongside increased cash burn, with near-term capital needed to fund planned operations.

Revenue breakdown: Royalty (100%).

8-K

Cadrenal Therapeutics entered into a warrant inducement agreement resulting in $2.5 million gross proceeds from exercising 571,430 existing warrants at $4.50/share and issuing new unregistered warrants for the same number of shares.

$11M

Market Cap

—

Revenue

-$16M

Net Income

Employees4

Fundamentals

How The Business Makes Money

Revenue by Segment

Royalty100%($200M)

Activity

What Changed Recently

Financial Results

Mar 30, 2026

and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securi

Material Agreement+3 More

Mar 31, 2026

of this Current Report on Form 8-K and Exhibit 10.1 to this Current Report on Form 8-K regarding the New Warrants are incorporated herein by reference. ** ** **

Regulation FD

Mar 11, 2026

and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securi

Other Event

Feb 23, 2026

. Other Events. On February 24, 2026, Cadrenal Therapeutics, Inc. (the “Company”) issued a press release announcing results from a Phase 2 trial evaluating CAD

Peer Companies

Company	Price	Change	Market Cap	P/E
NRXSNeurAxis, Inc.	$7.21	+0.42%	$81M	-8.5
RLYBRallybio Corporation	$8.38	-0.24%	$44M	-5.4
IBIOiBio, Inc.	$1.97	+0.77%	$31M	-8.9
XCURExicure, Inc.	$4.22	+0.96%	$27M	-3.0
NRSNNeuroSense Therapeutics L...	$0.83	+9.22%	$20M	-2.2
KLTOKlotho Neurosciences, Inc...	$0.38	-7.10%	$20M	—
TAOXTAO Synergies Inc.	$5.74	+0.20%	$20M	-0.6
SONNSONN	$1.26	-59.35%	$8M	—

Analyst View

Company Profile

CIK0001937993

ISINUS1276362076

Phone904 300 0701

Address822 A1A North, Ponte Vedra, FL, 32082, US

SEC EDGAR